Biopharma AI
By
At VivaTech 2025, Can NVIDIA, Sanofi, and TetraScience Unlock the Full Potential of Scientific AI Despite a 20-Exabyte Data Barrier?
Key Highlights The 20-Exabyte Problem: Data, Not Models, Is the Limiting FactorAt The Rise of Scientific AI panel…
Is AstraZeneca’s $20M AI Hub in Bengaluru the Catalyst for 20 New Medicines by 2030?
Key Highlights Strategic Investment to Scale AI-Driven InnovationAstraZeneca has inaugurated a state-of-the-art Global Hub in Bengaluru with an…
Can Lisata Therapeutics and GATC Health’s AI Breakthrough Redefine Drug Discovery and Tackle the Opioid Crisis in Just One Year?
Key Highlights AI-Powered Drug Discovery Moves Toward the Clinic with OUD FocusLisata Therapeutics and GATC Health have expanded…
Is Merck’s $10B Acquisition of Verona a Strategic Masterstroke to Offset Keytruda’s Patent Cliff and Dominate the $30B+ Respiratory Market?
Key Highlights Merck Secures Verona to Bridge Its Post-Keytruda Future Merck & Co. has taken a bold step…
How Will Eli Lilly’s New $220,000 sq ft Hyderabad Tech Hub and 1,500-Strong AI Workforce Transform Global Biopharma Innovation?
Key Highlights Strategic Digital Operations Hub Anchors Eli Lilly’s Global Innovation AmbitionsEli Lilly’s Hyderabad facility located in Gachibowli…
How Will METiS Technologies’ RMB 400 Million Series D Raise Accelerate Beijing’s AI-Powered Nanodelivery Revolution in Biopharma by 2027?
Key Highlights Strong Capital Infusion to Accelerate AI-Driven Nanotechnology DevelopmentThe recent RMB 400 million (~$57 million) financing round…
